收费全文 | 945篇 |
免费 | 190篇 |
国内免费 | 19篇 |
耳鼻咽喉 | 9篇 |
儿科学 | 23篇 |
妇产科学 | 8篇 |
基础医学 | 211篇 |
口腔科学 | 8篇 |
临床医学 | 56篇 |
内科学 | 81篇 |
皮肤病学 | 76篇 |
神经病学 | 32篇 |
特种医学 | 6篇 |
外国民族医学 | 1篇 |
外科学 | 43篇 |
综合类 | 44篇 |
预防医学 | 5篇 |
眼科学 | 5篇 |
药学 | 56篇 |
中国医学 | 1篇 |
肿瘤学 | 489篇 |
2024年 | 5篇 |
2023年 | 22篇 |
2022年 | 67篇 |
2021年 | 82篇 |
2020年 | 73篇 |
2019年 | 68篇 |
2018年 | 68篇 |
2017年 | 66篇 |
2016年 | 85篇 |
2015年 | 114篇 |
2014年 | 116篇 |
2013年 | 112篇 |
2012年 | 65篇 |
2011年 | 53篇 |
2010年 | 34篇 |
2009年 | 23篇 |
2008年 | 23篇 |
2007年 | 25篇 |
2006年 | 22篇 |
2005年 | 13篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 1篇 |
2001年 | 1篇 |
2000年 | 1篇 |
Areas covered: The aim of this article is to review the literature concerning eruptive melanocytic nevi following the administration of immunosuppressive drugs and other medications.
Expert opinion: The literature regarding the development of eruptive nevi in association with pharmacological therapies includes a relatively low number of reports. Prevalence of this phenomenon is likely to be underestimated, thus reporting should be encouraged in order to better define the actual significance and related clinical implications. The development of multiple melanocytic nevi during immunosuppressive treatments highlights the importance of immune system integrity in the regulation of nevi growth. The observation of eruptive nevi as an unexpected effect of targeted therapies for specific types of cancer, including melanoma, provided intriguing hints to understand the mechanisms underlying this paradoxical event. The synergistic role of additional triggers in the occurrence of drug-induced eruptive nevi has not been explored and may be an interesting area of research. 相似文献
Areas covered: The current scientific literature on safety and adverse events (AEs) related to BRAF and MEK-inhibition has been investigated with special focus on the large phase 3 studies (COMBI-v, COMBI-d and CoBRIM) as well as recent updates presented at oncology and melanoma meetings. Additionally, published case series/case reports were screened for information on AEs.
Expert opinion: Even though almost every patient (98%) under combination therapy with dabrafenib and trametinib experiences at least one adverse event, these are generally mild to moderate, reversible and can be managed with dose reductions or interruptions. However, due to an increased life expectancy, there is a substantial need to prevent and treat also mild adverse events, as they play a central role for the quality of life of patients. Ongoing clinical trials will have to demonstrate the efficacy as well as safety of triple combination with anti-PD-1/anti-PD-L1 antibodies. 相似文献